Introduction/Background HLA expression is associated with inflammation, is found on the of tumor cells and is insufficiently studied in endometrial pathology.
Purpose of the study: to determine the features of HLA-DR expression in the endometrium in normal, chronic endometritis, polyps, endometrial cancer.
Methodology HLA-DR expression in epithelium and stroma of 227 endometrial samples was assessed by immunohistochemistry: normal endometrium (NE, n=56), chronic endometritis (CE, n=139), endometrial polyps (EP,n=14), endometrioid endometrial adenocarcinoma (EA, n=18). The expression of HLA-DR on immune cells of stroma was designated as HLA-DR-im. The expression of HLA-DR in the epithelium was designated as HLA-DR-ep and divided into High expression( HLA-DRep+High - above 50% of the glands) and low (HLA-DRep- Low - less than 50%).
Results HLA-DR-im were observed in the stroma in all groups. HLA-DRep is heterogeneous in the endometrial epitelium. HLA-DRep negative expression was found in 55.6% of cases with AE; in 25.2% of cases with CE; in 27.7% with EP, in 100% of cases with NE (p<0.05, Mann-Whitney test). HLA-DRep+High was found in 21.6% for HE; in 28.6% for EP and in 16.7% for AE, it is associated with a high amount of HLA-DRim in the stroma (p<0.05 Mann Whitney) and significantly frequent detection of HLA-DR+ lymphoid follicles in AE (x2, p<0.05). HLA-DRep+Low is set to 51.8% at HE; in 27.8% with PE and in 27.7% of cases with AE and low content of HLA-DRim in stroma (p>0.05, Mann-Whitney test)
Conclusion Were identified two main types of HLA-DR expression in AE: HLA-DRep- and HLA-DRep+ (High and Low). We hypothesized that the HLA-DR expression of endometrial cancer cells associated with chronic inflammation and probably reflects a special mechanism of carcinogenesis which requires further complex molecular genetic research. HLA-DR expression in endometrial epithelial cells of chronic endometritis is a high risk factor for cancer.
Disclosures The authors declare no conflict of interest.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.